Troy Kemp, Ph.D.
Scientific manager, Serology Laboratory
Overview
Image
The COVID-19 Serology Laboratory establishes standards and coordinates research for the National Cancer Institute Serological Sciences Network (SeroNet).
At the start of the COVID-19 pandemic in March, 2020, our scientists pivoted to evaluate the performance of SARS-CoV-2 antibody tests for the U.S. Food and Drug Administration. As the NCI established SeroNet, the laboratory grew from its original HPV focus to address COVID-19 serology and immunology.
The COVID-19 Serology Laboratory provides expertise and leadership for SeroNet, which is the largest coordinated effort to better understand SARS-CoV-2 immune response.
Focus
COVID-19 Immune Response
- Provide expertise and direction for the Serological Sciences Network.
- Produce and distribute the U.S. Human SARS-CoV-2 Serology Standard in collaboration with the NCI, NIAID, NIH Clinical Center, WHO, and various other organizations including the National Institute of Standards and Technology and Biomedical Advanced Research and Development Authority.
- Develop, validate, and evaluate serology assays in collaboration with the FDA, NIAID, and other U.S. government agencies and academic groups.
Serology Standardization
- Develop, validate, and standardize serology assays, reagents, and procedures to enable the comparison of different studies evaluating immune responses induced by vaccines.
- Provide standardized resources to the scientific community.